-->

Tag: FDA-approved immunotherapy 2023

Home / FDA-approved immunotherapy 2023

Categories

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

  June 2024: Pembrolizumab (Keytruda, Merck) has been authorized by the Food and Drug Administration for the treatment of adult patients with primary, advanced, or recurrent endometrial cancer...
fda-approved-immunotherapy-2023

Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer

  June 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with carboplatin and paclitaxel, followed by singl...
fda-approved-immunotherapy-2023

Scan the code